New evidence supporting ZAP-X in uveal melanoma

ZAP-X
Written By Melissa McRae

Great to see fresh, peer-reviewed evidence backing ZAP Surgical Systems, Inc. in uveal melanoma.

This latest comparison with CyberKnife shows sharper conformity, steeper dose fall-off, and lower dose to critical structures.

Momentum is building for precision radiosurgery.

Melissa McRae
Previous

Alorium is heading to ANZSNM 2026 in Canberra.
Next

HealthTech 250 startups - Gosta Labs is shifting from innovation to implementation